New data from a phase 2b trial of Moderna and MSD’s neoantigen melanoma vaccine may be strong enough to consider filing for accelerated approval before a phase 3 programme
GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from the DREAMM-8 trial of the drug in multiple myel
Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its EVOKE-01 study, revealed for the first time at th
In this week’s clinical trials round-ups, we look at life sciences research and development announced during the week of 27th to 31st May, from early-stage onwards.